GSK heads into its July 28 Q2 results on a quiet improving trend — shares up 3% this week and 4.4% over the past month, while short sellers have reduced positions to their smallest level in over six weeks.
The most interesting development in positioning is the sharp retreat in short interest. At the latest reading, SI % of FF has fallen to 0.9% — down from a recent peak of 1.15% on May 29, and less than half the level recorded in mid-May when shorts briefly doubled their position from roughly 0.5% to above 1% following the Q1 earnings drop. That rapid build and quicker retreat suggests opportunistic, event-driven shorting rather than a structural bear thesis. With nearly 1.9 billion shares still available to borrow and availability at essentially uncapped levels, the lending market is about as loose as it gets. Cost to borrow has ticked up about 11% over the past week to 0.62%, which is a move but still firmly in "cheap" territory — no sign of borrow stress. The ORTEX short score of 33 is at the lower end of recent readings, consistent with diminished short-side conviction.
The Street is cautiously constructive but not enthusiastic. The consensus sits at hold, with 6 buys against 12 holds and a mean price target of £20.83 — about 7.5% above Friday's close of £19.38, suggesting the market is priced for modest upside rather than a re-rating. Valuation multiples have moved in the right direction: the P/E has expanded to 10.4x and P/B to 3.9x, both up around 4-5% over the past 30 days, consistent with the price recovery. EV/EBITDA at 7.8x has drifted slightly lower over the same period. The EV/EBIT factor ranks in the 78th percentile of the universe — GSK screens as reasonably priced on earnings power. The dividend score ranks in the 94th percentile, which should anchor income-oriented holders, though available dividend data in this snapshot is stale and cannot be quoted directly.
Ownership is stable and skewed toward long-only institutions. BlackRock leads with 10.3% of shares and added 7.5 million shares in its most recent filing. Fidelity (FMR) added over 20 million shares to reach 4.8%, the largest percentage addition among major holders. That contrasts with the GlaxoSmithKline Employee Trust, which trimmed its position by 1.3 million shares — a modest net sell from an insider vehicle, though hardly alarming. On the individual insider side, director Wendy Becker bought shares twice in recent months at prices around £19.60–22.19, and an unnamed director added 6,335 shares in March. These are small in absolute terms but directionally positive, and they came at prices close to or above current levels. The 90-day net insider position is a marginal net buy when including award grants.
The earnings history adds a note of caution around the upcoming print. GSK's April 29 Q1 results produced a 4.9% single-day decline and a 7.5% drawdown over the following five sessions — the largest adverse reaction in recent history. The May 6 event, by contrast, was essentially flat on the day. That asymmetry — sharp drops on misses, muted responses to beats — is worth keeping in mind as July 28 approaches. Peer AZN gained just 0.4% on the week versus GSK's 3%, while Sanofi matched GSK more closely with a 3.5% weekly gain, suggesting this week's move reflects some GSK-specific recovery rather than a pure sector lift.
The next focal point is Q2 results on July 28. Between now and then, the key question is whether the vaccine and oncology revenue trends flagged in Q1 show any stabilisation — that read, more than valuation or short positioning, will determine whether the current recovery has legs.
See the live data behind this article on ORTEX.
Open GSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
